Journal of Clinical Oncology, Vol 20, Issue 1
(January), 2002: 353
© 2002 American Society for Clinical Oncology
Replacement of Carboplatin by Oxaliplatin May be One Solution for Patients Treated for Ovarian Carcinoma Who Are Hypersensitive to Carboplatin
M. Gutierrez,
P. Pautier,
C. Lhommé
Institut Gustave Roussy, Villejuif, France
To the Editor:We were impressed by the recently published article about carboplatin skin testing.1 This interesting and original study shows us a way to predict hypersensitivity to carboplatin, a real problem in clinical practice. Despite prophylaxis, some patients develop a hypersensitivity reaction to carboplatin. The risk for a reaction increases with an increased number of cycles.
Platin salts are considered to be one of the major drugs for first-line treatment and for platinum-sensitive recurrence of ovarian carcinoma. Although desensitization has been used successfully,2 some severe cases of reactions have been reported for cisplatin or carboplatin despite desensitization, including anaphylaxis and death.3 Oxaliplatin is a platin salt which has been compared with cisplatinum in an ovarian cancer first-line therapy in a multicenter phase II/III study. No significant differences were found for the efficacy parameters between the two arms.4,5 Although some allergic reactions have been reported with oxaliplatin,6 no cross-reactivity has been found in the literature between oxaliplatin and carboplatin or between oxaliplatin and cisplatin.
We report two cases of patients with a platinum-sensitive recurrence of ovarian carcinoma treated with oxaliplatin after a severe allergic reaction to carboplatin. Before the allergic reactions, they had previously received 11 and 13 courses of carboplatin. Allergic reactions appeared at the fifth and fourth cycle of carboplatin for relapsed disease. Subsequently, three and five courses of oxaliplatin were administered under clinical surveillance during a short hospitalization. No hypersensitivity or minor reactions were reported. In both cases, however, the disease continues to respond. Replacement of carboplatin by oxaliplatin under clinical surveillance may be a solution for patients treated for ovarian carcinoma and developing a hypersensitivity to carboplatin.
REFERENCES
1.
Zanotti K, Rybicki LA, Kennedy AW, et al: Carboplatin skin testing: A skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 19: 3126-3129, 2001[Abstract/Free Full Text]
2.
Broom CB, Schiff RI, Friedman HS: Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 26: 105-110, 1996[CrossRef][Medline]
3.
Zweizig S, Roman LD, Muderspach LI: Death from anaphylaxis to cisplatin: A case report. Gynecol Oncol 53: 121-122, 1994[CrossRef][Medline]
4.
Shlebak AA, Clark PI, Green JA: Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 35: 349-351, 1995[Medline]
5.
Misset JL, Vennin P, Chollet P, et al: Multicenter phase II/III study of oxaliplatin plus cyclophosphamide (C) [OXC] versus cisplatin (P) plus cyclophosphamide [CPC] in advanced chemonaive ovarian cancer (AOC) patients: Final results. Proc Am Soc Clin Oncol 19: 380a, 2000 (abstr 1502)
6.
Tournigand C, Maindrault-Goebel F, Louvet C, et al: Severe anaphylactic reactions to oxaliplatin. Eur J Cancer 34: 1297-1928, 1998 (letter)
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. K. Crook and T. A. Guise
RANKL: Targeting Bone and Cancer to Treat Skeletal Complications of Malignancy
IBMS BoneKEy,
September 1, 2009;
6(9):
323 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Marathe, M. C. Peterson, and D. E. Mager
Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients
J. Pharmacol. Exp. Ther.,
August 1, 2008;
326(2):
555 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev.,
April 1, 2008;
29(2):
155 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, G. Toraldo, A. Li, X. Yang, H. Zhang, W.-P. Qian, and M. N. Weitzmann
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo
Blood,
May 1, 2007;
109(9):
3839 - 3848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Heath, K. Vanderkerken, X. Cheng, O. Gallagher, M. Prideaux, R. Murali, and P. I. Croucher
An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma
Cancer Res.,
January 1, 2007;
67(1):
202 - 208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Matsumoto and M. Abe
Myeloma-Bone Interaction: A Vicious Cycle
IBMS BoneKEy,
March 1, 2006;
3(3):
8 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Bharti, S. Shishodia, J. M. Reuben, D. Weber, R. Alexanian, S. Raj-Vadhan, Z. Estrov, M. Talpaz, and B. B. Aggarwal
Nuclear factor-{kappa}B and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
Blood,
April 15, 2004;
103(8):
3175 - 3184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Younes and M. E. Kadin
Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy
J. Clin. Oncol.,
September 15, 2003;
21(18):
3526 - 3534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
